Daniel Claassen

Low-flow cerebrospinal fluid in Huntington’s disease: study

Vanderbilt researchers found reduced net flow of cerebrospinal fluid in Huntington’s disease, which could contribute to mutant protein retention and altered responsiveness to medications delivered via the spinal cord.

Neurofluid flow and Alzheimer’s disease

Vanderbilt researchers used novel MRI methods to noninvasively quantify measures of neurofluid circulation and found that hypertrophy of a site of cerebrospinal fluid egress may be related to amyloid-beta retention in Alzheimer’s disease.

Study examines impulsiveness in Parkinson’s disease

Vanderbilt researchers are studying aspects of dopamine release and its regulation in Parkinson’s patients with and without impulsive-compulsive behaviors.

Danielle Buchanan, BS, right, and Daniel Claassen, MD, MS, are studying the relationship between clinical research coordinators principal investigators. (photo by Donn Jones)

Survey identifies factors in reducing clinical research coordinator turnover

Strong, collaborative relationships with principal investigators are a key factor of longevity in clinical research coordinator positions — an essential, but increasingly transient job in executing treatment-advancing clinical trials, Vanderbilt University Medical Center researchers found.

Impulsivity in Parkinson’s Disease

A noninvasive MRI technique may help predict a troubling side effect of common medications for Parkinson’s Disease and improve clinical treatment plans.

Huntington’s Disease Clinic lands Level 1 designation

The Vanderbilt University Medical Center (VUMC) Huntington’s Disease Clinic is one of only four in the nation to receive a Level 1 Center of Excellence designation.